![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com//news-release/2023/10/02/2752648/0/en/A-Special-Protocol-Assessment-Agreement-Reached-with-the-U-S-Food-and-Drug-Administration-for-Phase-3-clinical-trial-of-Sovateltide-for-the-treatment-of-acute-cerebral-ischemic-str.html
https://www.prnewswire.com/news-releases/pharmazz-inc-announces-us-fda-clearance-for-a-phase-iii-clinical-trial-of-sovateltide-pmz-1620-in-acute-cerebral-ischemic-stroke-patients-301744465.html
https://www.prnewswire.com/news-releases/clinical-phase-iii-trial-results-demonstrating-sovateltides-efficacy-to-treat-acute-cerebral-ischemic-stroke-presented-at-the-international-stroke-conference-2023-301741886.html
https://www.globenewswire.com/news-release/2022/10/31/2544513/0/en/Pharmazz-Inc-Presents-Positive-Results-of-Phase-III-Clinical-Trial-Demonstrating-Sovateltide-s-Efficacy-as-a-Treatment-for-Acute-Cerebral-Ischemic-Stroke.html
https://www.globenewswire.com/news-release/2022/08/29/2505915/0/en/Pharmazz-Inc-announces-Indian-Central-Drugs-Standard-Control-Organization-CDSCO-Clearance-of-IND-to-conduct-a-Phase-II-clinical-trial-of-sovateltide-PMZ-1620-in-hypoxic-ischemic-en.html
https://www.globenewswire.com/news-release/2022/02/17/2387114/0/en/Pharmazz-Inc-Announces-Completion-of-Enrollment-of-Phase-III-Clinical-Trial-Evaluating-Sovateltide-as-a-Treatment-for-Acute-Cerebral-Ischemic-Stroke.html
https://www.globenewswire.com/news-release/2022/02/03/2378487/0/en/Pharmazz-Inc-submits-Investigational-New-Drug-Application-to-India-Central-Drugs-Standard-Control-Organization-for-a-Phase-II-clinical-trial-of-sovateltide-PMZ-1620-in-hypoxic-isch.html